Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

6 december 2020 uppdaterad av: Novartis Pharmaceuticals

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Age, Sex, and Body Weight-matched Healthy Subjects

The aim of this study was to characterize the pharmacokinetics and safety of AFQ056 in subjects with a different degree of renal impairment.

Studieöversikt

Status

Avslutad

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

48

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Kiel, Tyskland
        • Novartis Investigative Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Written informed consent must be obtained before any assessment is performed.
  • Female subjects must be of non-child bearing potential as defined as postmenopausal females with no regular menstrual bleeding for at least 1 year prior to inclusion
  • Body weight: ≥50kg; BMI: 18-34 kg/m2
  • Ability to communicate well with the investigator and comply with the requirements of the study.

For subjects with renal impairment only

  • No current clinically significant disease (other than renal impairment), except for stable underlying disease that caused renal impairment, as determined by clinical history and physical examination.
  • MDRD-calculated eGFR of <90 mL/min/1.73 m2 based on serum creatinine
  • Vital signs (after 3 minutes resting measured in the supine position) should be within normal ranges as deemed by the Investigator.

For healthy subjects only

  • No current clinically significant disease as determined by clinical history and physical examination.
  • MDRD-calculated eGFR of ≥90 mL/min/1.73 m2 based on serum creatinine.
  • Vital signs (after 3 minutes resting measured in the supine position) should be within normal ranges as deemed by the Investigator.

Exclusion Criteria:

  • Pregnant or nursing (lactating) females
  • Use of any prescription or over-the-counter (OTC) drugs, herbal (e.g. St. John's wort) ordietary supplements (e.g. broccoli, vitamins) within three weeks or five half lives(whichever is longer) prior to dosing with AFQ056 until study completion. This does not include drugs that are used as (symptomatic) treatment of renal impairment (e.g. antihypertensive and antidiabetic drugs) provided such drugs are:

    • used at the same dose within three weeks or five half lives (whichever is longer) prior to dosing with AFQ056 until study completion.
    • not known as inhibitors or inducers of CYP1A1, 1A2, 2C8, 2C9, 2C19, 3A4, 3A5 gp).
  • Participation in any clinical investigation or use of any investigational drug within 30 days or five (5) half-lives of a given investigational drug (whichever period is longer); or longer if required by local regulations prior to screening until study completion
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
  • History of renal transplantation
  • History or presence of prolonged QTc interval (males: >450ms; females: > 470 ms), 2nd or 3rd degree AV-block or any other clinically significant ECG abnormalities as determined by medical history and 12-lead ECG recordings at screening and baseline 1.
  • History or presence of any clinically significant disease of any major system organ class, within the past 2 years prior to screening, except for renal impairment and underlying diseases causing renal impairment for the subject belonging to the renal impairment groups.
  • Subjects undergoing any method of dialysis (hemodialysis or peritoneal dialysis)
  • History of or ongoing active substance abuse (including alcohol) within the past 2 years.
  • Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will be measured during Screening and at Baseline for all subjects. Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine ≥ 500 ng/mL at screening

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: N/A
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: All study subjects

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Measure: Area under the plasma concentration-time curve from time zero to infinity (AUCinf)
Tidsram: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Area under the curve from time zero to the last measurable concentration sampling time (Tlast) [mass x time x volume-1] (AUClast)
Tidsram: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Maximum observed plasma concentration (Cmax)
Tidsram: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tidsram: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Terminal elimination half-life (T1/2)
Tidsram: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: The apparent systemic (or total body) clearance from plasma following extravascular administration [volume / time] (CL/F)
Tidsram: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: The apparent volume of distribution during the terminal elimination phase following oral administration [volume] (Vz/F)
Tidsram: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Amount of drug excreted into the urine from time zero to time't' where t is a defined time point after administration [mass units or % of dose] (Ae0-t)
Tidsram: 4 days
4 days
Measure: The renal clearance from plasma [volume / time] (CLr)
Tidsram: 4 days
4 days

Sekundära resultatmått

Resultatmått
Tidsram
Physical examination
Tidsram: Screening, Day -1, Day 8 +/- 2 days
Screening, Day -1, Day 8 +/- 2 days
Measure: Vital signs and body measurements
Tidsram: Screening, Day -1, Day 1, Day 8 +/- 2 days
Screening, Day -1, Day 1, Day 8 +/- 2 days
Measure: ECG
Tidsram: Screening, Day -1, Day 1, Day 8 +/- 2 days
Screening, Day -1, Day 1, Day 8 +/- 2 days
Measure: pulse oximetry
Tidsram: Screening, Day -1, Day 1, Day 8 +/- 2 days
Screening, Day -1, Day 1, Day 8 +/- 2 days
Measure: hematology
Tidsram: Screening, Day -1, Day 4, Day 8 +/- 2 days
Screening, Day -1, Day 4, Day 8 +/- 2 days
Measure: blood chemistry
Tidsram: Screening, Day -1, Day 2, Day 4, Day 8 +/- 2 days
Screening, Day -1, Day 2, Day 4, Day 8 +/- 2 days
Measure: urinalysis
Tidsram: Screening, Day -1, Day 4, Day 8 +/- 2 days
Screening, Day -1, Day 4, Day 8 +/- 2 days
Measure: AE (adverse events) monitoring
Tidsram: During the study (up to 10 days)
During the study (up to 10 days)
SAE (serious adverse events) monitoring
Tidsram: During the study (up to 10 days) and up to 30 days after study completion
During the study (up to 10 days) and up to 30 days after study completion

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 januari 2011

Primärt slutförande (Faktisk)

1 augusti 2011

Avslutad studie (Faktisk)

1 augusti 2011

Studieregistreringsdatum

Först inskickad

9 september 2011

Först inskickad som uppfyllde QC-kriterierna

27 september 2011

Första postat (Uppskatta)

28 september 2011

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

8 december 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 december 2020

Senast verifierad

1 februari 2017

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • CAFQ056A2124
  • 2010-022738-94 (EudraCT-nummer)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera